Orexigen Therapeutics, Inc.  

(Public, NASDAQ:OREX)   Watch this stock  
Find more results for OREX
0.376
-0.035 (-8.41%)
After Hours: 0.380 0.000 (0.00%)
May 6, 5:32PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.38 - 0.42
52 week 0.38 - 6.96
Open 0.42
Vol / Avg. 2.87M/2.45M
Mkt cap 51.57M
P/E     -
Div/yield     -
EPS -0.54
Shares 145.56M
Beta 2.26
Inst. own 91%
Aug 4, 2016
Q2 2016 Orexigen Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 8, 2016
Orexigen Therapeutics Inc Annual Shareholders Meeting (Estimated) - 1:00PM EDT - Add to calendar
May 10, 2016
Orexigen Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference - 4:00PM EDT - Add to calendar
May 4, 2016
Q1 2016 Orexigen Therapeutics Inc Earnings Call - Webcast
May 4, 2016
Q1 2016 Orexigen Therapeutics Inc Earnings Release
Mar 15, 2016
Orexigen Therapeutics Inc to Discuss Acquisition of U.S. Rights to Contrave and the Central and Eastern European Partnership with Valeant Pharmaceuticals International, Inc. Conference Call - Webcast
Feb 26, 2016
Q4 2015 Orexigen Therapeutics Inc Earnings Release
Feb 26, 2016
Q4 2015 Orexigen Therapeutics Inc Earnings Call - Webcast
Feb 24, 2016
Orexigen Therapeutics Inc at RBC Capital Markets Healthcare Conference - Webcast
Feb 11, 2016
Orexigen Therapeutics Inc at Leerink Partners Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -444.03% -280.82%
Operating margin -463.32% -245.53%
EBITD margin - -244.61%
Return on average assets - -30.56%
Return on average equity - -246.53%
Employees 67 -
CDP Score - -

Address

3344 N Torrey Pines Ct Ste 200
LA JOLLA, CA 92037-1024
United States - Map
+1-858-8758600 (Phone)
+1-858-8758650 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company. The Company is focused on the development of pharmaceutical product candidates for the treatment of obesity. The Company's product is Contrave, a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER. The Company's product Contrave, is approved in the United States by the United States Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI), of around 30 kilograms per square meter (kg/m2) or greater (obese), or around 27 kilograms per square meter or greater (overweight) in the presence of at least one weight-related comorbid condition. The Company also submitted an application for marketing authorization with the European Medicines Agency (EMA) for Contrave under the name Mysimba.

Officers and directors

Eckard Weber M.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Michael A. Narachi President, Chief Executive Officer, Interim Chief Financial Officer, Director
Age: 55
Bio & Compensation  - Reuters
Thomas P Lynch Executive Vice President, General Counsel, Secretary
Bio & Compensation  - Reuters
Thomas Cannell Executive Vice President, Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
Preston S. Klassen M.D. Senior Vice President, Head of Global Development
Age: 46
Bio & Compensation  - Reuters
Chris Hazuka Acting General Counsel
Bio & Compensation  - Reuters
Louis C. Bock Independent Director
Age: 50
Bio & Compensation  - Reuters
Brian H. Dovey Independent Director
Age: 74
Bio & Compensation  - Reuters
David J. Endicott Independent Director
Age: 50
Bio & Compensation  - Reuters
Peter K. Honig M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters